Nkarta Inc

NASDAQ NKTX

Data sourced from

and

Download Data

Nkarta Inc Cash Dividend Coverage Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Nkarta Inc Cash Dividend Coverage Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. The cash dividend coverage ratio assesses a company's ability to cover its dividend payments with its operating cash flow. It is calculated by dividing operating cash flow by dividends paid. This ratio indicates the company's capacity to generate sufficient cash flow to support dividend distributions. A ratio greater than 1 indicates a healthy coverage of dividends, while a ratio less than 1 suggests potential challenges in meeting dividend obligations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: NKTX

Nkarta Inc

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	150
Sector	Healthcare
Industry	Biotechnology

Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends